Will Rybrevant receive EMA approval by the end of 2024? | Binary | | | 3 months ago | |
Will Rybrevant reach $5 billion in sales by end of 2024? | Binary | | | 3 months ago | |
Will Johnson & Johnson stock price increase by 10% within one month of Rybrevant approval? | Binary | | | 3 months ago | |
What will be Rybrevant's sales figures for Q4 2024? | Categorical | | | 3 months ago | |
How many new indications will Rybrevant receive FDA approval for by end of 2025? | Categorical | | | 3 months ago | |
Will Rybrevant achieve $5 billion in sales by the end of 2024? | Binary | | | 3 months ago | |
Will Rybrevant receive another FDA approval for a new indication by end of 2024? | Binary | | | 3 months ago | |
Will Rybrevant sales reach $1 billion in the US by end of 2024? | Binary | | | 3 months ago | |
Will Rybrevant achieve its $5 billion sales target by end of 2025? | Binary | | | 3 months ago | |
Will Rybrevant reach $5 billion in sales by the end of 2024? | Binary | | | 3 months ago | |
Will J&J announce a new Phase III trial for Rybrevant in colorectal cancer by mid-2025? | Binary | | | 3 months ago | |
Will J&J's new prophylactic strategies further reduce infusion-related reactions by March 31, 2025? | Binary | | | 3 months ago | |
Will J&J receive FDA approval for the new prophylactic regimen for Rybrevant by the end of 2024? | Binary | | | 3 months ago | |
Will J&J's stock price increase by more than 10% by the end of 2024? | Binary | | | 3 months ago | |
What will be Rybrevant's market share in the EGFR-mutated lung cancer treatment segment by end of 2024? | Categorical | | | 3 months ago | |
Will Rybrevant be included in NCCN Guidelines for lung cancer by end of Q1 2025? | Binary | | | 3 months ago | |
How will Johnson & Johnson's stock price change by the end of 2024 following Rybrevant's approval? | Categorical | | | 3 months ago | |
Will Rybrevant be approved in the EU by June 30, 2025? | Binary | | | 3 months ago | |
Will Rybrevant receive another FDA approval for a new indication by December 31, 2025? | Binary | | | 3 months ago | |
What will be the sales of Rybrevant by the end of 2024? | Categorical | | | 3 months ago | |
Which major market will approve Rybrevant next by the end of 2024? | Categorical | | | 3 months ago | |
What will Johnson & Johnson's total revenue from oncology drugs be in 2024? | Categorical | | | 3 months ago | |
What will be the next FDA approval for Rybrevant by end of 2024? | Categorical | | | 3 months ago | |
What will Rybrevant sales in the US be for 2024? | Categorical | | | 3 months ago | |
What will be Rybrevant's market share among second-line treatments for EGFR-mutated advanced lung cancer by the end of 2024? | Categorical | | | 3 months ago | |
In how many countries will Rybrevant be approved by the end of 2024? | Categorical | | | 3 months ago | |
What will be Rybrevant's sales in Q4 2024? | Categorical | | | 3 months ago | |
Will Rybrevant be approved as a first-line treatment for EGFR-mutated advanced lung cancer by the end of 2024? | Binary | | | 3 months ago | |
What will be the overall response rate of Rybrevant in metastatic colorectal cancer patients by end of 2024? | Categorical | | | 3 months ago | |
Will Rybrevant be FDA approved for metastatic colorectal cancer by mid-2025? | Binary | | | 3 months ago | |
Will Rybrevant show a higher overall survival rate in EGFR-mutated lung cancer patients by end of 2024? | Binary | | | 3 months ago | |
What will be the market share of Rybrevant in EGFR-mutated lung cancer treatment by end of 2025? | Categorical | | | 3 months ago | |
How many new indications will Rybrevant be FDA approved for by end of 2025? | Categorical | | | 3 months ago | |
What will be the primary endpoint result of J&J's ongoing studies on new prophylactic strategies for Rybrevant by March 31, 2025? | Categorical | | | 3 months ago | |
What will be the rate of infusion-related reactions in J&J's ongoing studies with new prophylactic strategies by March 31, 2025? | Categorical | | | 3 months ago | |
Which prophylactic strategy will be found most effective in J&J's ongoing studies by March 31, 2025? | Categorical | | | 3 months ago | |
